NCT06055621View on ClinicalTrials.gov

Evaluation of DASATINIB Monotherapy Efficacy in Acute Myeloid Leukemia Patients Refractory to VENETOCLAX-AZACITIDINE

PHASE2RecruitingINTERVENTIONAL

Enrollment

35

Participants

Timeline

Start Date

May 22, 2024

Primary Completion Date

October 31, 2025

Study Completion Date

October 31, 2027

Conditions

Acute Myeloid Leukemia

Interventions

DRUG

Dasatinib

Daily orally administration of DASATINIB

Trial Locations (1)

Unknown

RECRUITING

Institut Paoli Calmettes, Marseille

All Listed Sponsors

lead

Institut Paoli-Calmettes

OTHER